Samantha Pearce - Feb 2, 2023 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
SVP, Head of Europe & Internat
Signature
By: Adam Guttman, as attorney in fact For: Samantha J. Pearce
Stock symbol
JAZZ
Transactions as of
Feb 2, 2023
Transactions value $
-$25,387
Form type
4
Date filed
2/6/2023, 03:26 PM
Previous filing
Jan 5, 2023
Next filing
Mar 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Options Exercise $58.1K +531 +4.7% $109.45 11.8K Feb 2, 2023 Direct F1
transaction JAZZ Ordinary Shares Sale -$83.5K -531 -4.48% $157.26 11.3K Feb 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAZZ Non-Qualified Stock Option (right to buy) Options Exercise $0 -531 -7.14% $0.00 6.91K Feb 2, 2023 Ordinary Shares 531 $109.45 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Samantha Pearce is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.